Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
13 févr. 2025 06h31 HE
|
Agios Pharmaceuticals, Inc.
– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European...
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
13 févr. 2025 06h30 HE
|
Agios Pharmaceuticals, Inc.
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – – Safety Results Consistent with Safety Profile for...
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
06 févr. 2025 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios to host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m. ET to report its 4Q and full year 2024 financials.
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
13 janv. 2025 07h00 HE
|
Agios Pharmaceuticals, Inc.
– FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date...
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
08 janv. 2025 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare...
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
03 janv. 2025 07h00 HE
|
Agios Pharmaceuticals, Inc.
is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
18 déc. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare...
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
08 déc. 2024 12h40 HE
|
Agios Pharmaceuticals, Inc.
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
05 nov. 2024 09h05 HE
|
Agios Pharmaceuticals, Inc.
Agios announced new data on mitapivat and tebapivat (AG-946) will be featured in oral and poster presentations during the ASH Annual Meeting.
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
31 oct. 2024 06h30 HE
|
Agios Pharmaceuticals, Inc.
Agios reports business highlights and financial results for the third quarter, ended September 30, 2024.